Rapport Therapeutics stock fell about 18% after investors reacted to updates on its lead drug candidate RAP-219, which shows strong efficacy in reducing focal onset seizures by up to 90%. The company is preparing for Phase 3 trials with optimism based on this data. Analysts are also awaiting Phase 2 bipolar mania trial results, which are expected to provide important safety insights rather than efficacy. Despite recent stock volatility, the company is viewed as a long-term buy due to solid clinical data, a strong cash position, and the potential blockbuster status of RAP-219.
Rapport Therapeutics shares fell sharply after recent clinical updates. For readers following the health sector, here is Pluang's market snapshot as of Sep 24, 2026 21:45 WIB: 58 of 100 priced health-sector US stocks rose today. Notable movers include Agilent Technologies Inc, which gained 3.70%, while Cassava Sciences Inc and Oscar Health Inc declined by 3.95% and 3.80%, respectively.
Analysts have mixed views on VICI Properties, a REIT focused on gaming and hospitality properties, with some lowering price targets due to refinancing costs and rent growth limits. Despite these concerns, the company maintains strong fundamentals inc...
Roth Capital upgraded Okta's price target from $155 to $235 and maintained a Buy rating following the company's new AI agent identity strategy unveiled at its Investor Summit. Okta aims to expand beyond traditional identity management by securing AI ...
Vecima Networks reported strong quarterly results with revenue of $64.04 million, surpassing the $55.69 million estimate, and earnings per share of $0.15, beating the $0.14 forecast. The company, a broadband technology provider for cable and fiber op...
Bernstein upgraded Dollar General to "Outperform" due to its strategic initiatives targeting budget shoppers and expanding seasonal product offerings, especially affordable toys. The company is also growing its DG Media Network, which generates signi...
TD SYNNEX reported quarterly earnings per share of $5.68, surpassing analyst estimates of $4.70 by 22.41%, and revenue of $21.56 billion, beating estimates by 14.81%. This strong performance reflects a 37.7% revenue increase year-over-year, driving t...
